A Phase 2 interventional study of Elamipretide and Placebo in Skeletal Muscle Mitochondrial Dysfunction in the Elderly, sponsored by Stealth BioTherapeutics Inc.. Completed at 1 site in United States. Open to participants aged 60 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-06-23.
Sponsored by Stealth BioTherapeutics Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Mitochondrial Diseases with a site in United States — 20 open to participants now, 22 under way, 3 of them phase 3. Mitochondrial Diseases · United States.
Among the 83 studies in Mitochondrial Diseases with a site in United States, this one is the 23rd largest by enrollment of the 50 interventional ones that give a count, is one of 4 that started in 2015, is one of 16 in phase 2, and was the 36th registered.
189 studies on the registry are indexed under Mitochondrial Diseases; 60 are open to participants now.
Browse Mitochondrial Diseases studies →20 of the 83 studies in Mitochondrial Diseases with a site in United States are open now. Recruiting first, the newest first:
Pharming Technologies B.V. · Sites in United States, Belgium, Czechia and 6 more countries
Ages 18+
Khondrion BV · Sites in United States, Denmark, France and 4 more countries
Ages 18+
Children's Hospital of Philadelphia · Sites in United States
Ages 8–75 · Healthy volunteers
Children's Hospital of Philadelphia · Sites in United States
Ages 18–65 · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 50+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 41 Mitochondrial Diseases studies recruiting now, 20 (49%) set no upper age limit and 14 (34%) stop at 75 or younger; 19 take children under 18; 17 take healthy volunteers.
This study: 60 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 21 · Phase 3 11 · Phase 4 3
First in 2000; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is above the median of 35 across 114 interventional studies indexed under Mitochondrial Diseases.
Median enrollment 38 across the 50 interventional studies, 61 across the 31 observational. Of the 54 that completed or were terminated, 23 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 83 have an industry lead sponsor. The 10 most frequent:
This study is registered under Stealth BioTherapeutics Inc., one of the names counted as Mighty Therapeutics. Under that name alone:
Stealth BioTherapeutics Inc. is the lead sponsor of 30 studies on the registry; 3 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Mighty Therapeutics has 4 studies filed under Mitochondrial Diseases — fewer than ten, so there is no comparison to draw.
9 of the studies in Mitochondrial Diseases with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05422534Phase 3Vanderbilt University Medical CenterCoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease | 2027-06-20 |
| NCT01803906Columbia UniversityTissue Sample Study for Mitochondrial Disorders | 2026-12 |
| NCT02000284University of ArkansasMitochondrial Dysfunction in Autism Spectrum Disorder | 2026-12-31 |
| NCT01694940Columbia UniversityNorth American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | 2026-12-31 |
| NCT03639701Columbia UniversityTreatment of TK2 Deficiency With Thymidine and Deoxycytidine | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 83 studies in Mitochondrial Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a Phase 2, randomized, double-blind, placebo-controlled study, enrolling 41 elderly subjects with previous evidence of mitochondrial dysfunction to evaluate whether the administration of MTP-131 (elamipretide) will change either hand skeletal muscle energetics or muscle performance in age-related skeletal muscle mitochondrial dysfunction.
This was a Phase 2, randomized, double-blind, placebo-controlled study, enrolling 41 elderly subjects with previous evidence of mitochondrial dysfunction to evaluate whether the administration of MTP-131 (elamipretide) will change either hand skeletal muscle energetics or muscle performance in age-related skeletal muscle mitochondrial dysfunction.
Subjects were randomized 1:1 to receive either elamipretide at 0.25 mg/kg/hr intravenously at a rate of 60 mL/hr for 2 hours, or placebo (lyophilized excipients without elamipretide) intravenously at a rate of 60 mL/hr for 2 hours. Each treatment group went through three distinct periods: Screening (up to 28 days), Treatment (1day), and Observation (7 days).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Elamipretide given as an intravenous infusion of 0.25 mg/kg/hr at a rate of 60 mL/hr for 2 hours.
Drug: Elamipretide
Placebo (lyophilized excipients without elamipretide) given as an intravenous infusion at a rate of 60 mL/hr for 2 hours.
Drug: Placebo
Elamipretide 0.25 mg/kg/hour administered as an intravenous infusion at the rate of 60 mL/hour for 2 hours
Also known as: MTP-131, Bendavia™
Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours
Also known as: elamipretide
Change From Baseline in ATPmax (Maximal ATP Synthetic Rate)
Maximal ATP synthetic rate (phosphorylation capacity per unit muscle volume) as determined by a muscle fatigue test.
Time frame: From Baseline, Day 1 Hour 2 (2 hours after the start of infusion, or end of infusion) and Day 7
Mean Change From Baseline in Phosphate/Oxygen (P/O) Ratio
As a measure of mitochondrial hand skeletal muscle energetics, mitochondrial coupling, or Phosphate/Oxygen ratio (P/O) was assessed at Baseline, Day 1 Hour 2, and Day 7.
Time frame: From Baseline, Day 1 Hour 2 (2 hours after the start of infusion, or end of infusion) and Day 7
Mean Change From Baseline in Nicotine Adenine Dinucleotide (NAD)
Time frame: From Baseline, Day 1 Hour 2 (2 hours after the start of infusion, or end of infusion) and Day 7
Mean Change From Baseline in Muscle Force-Time-Integral (FTI)
Muscle Force-Time-Integral was measured as mean change from baseline at Day 1 Hour 2, Day 3, and Day 7.
Time frame: From Baseline to Day 1 Hour 2, Day 3, and Day 7
| Milestone | Elamipretide | Placebo |
|---|---|---|
| Started | 20 | 21 |
| Completed | 19 | 20 |
| Not completed | 1 | 1 |
| Withdrew: Physician decision | 1 | 1 |
Maximal ATP synthetic rate (phosphorylation capacity per unit muscle volume) as determined by a muscle fatigue test.
| mM/sec | MTP-131 (Bendavia™) | Placebo |
|---|---|---|
| Day 1 Hour 2 | 0.17 ± 0.196 | 0.12 ± 0.244 |
| Day 7 | 0.09 ± 0.142 | 0.06 ± 0.172 |
As a measure of mitochondrial hand skeletal muscle energetics, mitochondrial coupling, or Phosphate/Oxygen ratio (P/O) was assessed at Baseline, Day 1 Hour 2, and Day 7.
| ratio of phosphate to oxygen | MTP-131 (Bendavia™) | Placebo |
|---|---|---|
| Day 1 Hour 2 | 0.25 ± 0.679 | 0.26 ± 0.693 |
| Day 7 | 0.32 ± 0.473 | 0.51 ± 0.788 |
| millimolar | MTP-131 (Bendavia™) | Placebo |
|---|---|---|
| Day 1 Hour 2 | 0.04 ± 0.169 | 0.01 ± 0.213 |
| Day 7 | 0.11 ± 0.215 | 0.09 ± 0.263 |
Muscle Force-Time-Integral was measured as mean change from baseline at Day 1 Hour 2, Day 3, and Day 7.
| Newton/second | MTP-131 (Bendavia™) | Placebo |
|---|---|---|
| Day 1 Hour 2 | 0.43 ± 0.882 | 0.10 ± 0.728 |
| Day 3 | 0.46 ± 1.036 | 0.24 ± 0.948 |
| Day 7 | 0.83 ± 1.485 | 0.44 ± 1.114 |
Collected over 36 days. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Elamipretide | 0/19 (0%) | 0/19 (0%) | 3/19 (15.8%) |
| Placebo | 0/20 (0%) | 0/20 (0%) | 2/20 (10%) |
| Event | Elamipretide | Placebo |
|---|---|---|
| DizzinessNervous system disorders | 1/19 | 0/20 |
| PalpitationsCardiac disorders | 1/19 | 0/20 |
| Herpes zosterInfections and infestations | 1/19 | 0/20 |
| Sinus congestionRespiratory, thoracic and mediastinal disorders | 1/19 | 0/20 |
| HeadacheNervous system disorders | 0/19 | 1/20 |
| NauseaGastrointestinal disorders | 0/19 | 1/20 |
| Vessel puncture site bruiseGeneral disorders | 0/19 | 1/20 |
| Age, Continuous(years) | MTP-131 (Bendavia™) | Placebo | Total |
|---|---|---|---|
| Mean | 67.9 ± 3.35 | 69.0 ± 3.96 | 68.5 ± 3.67 |
| Sex: Female, Male(Participants) | MTP-131 (Bendavia™) | Placebo | Total |
|---|---|---|---|
| Female | 11 | 7 | 18 |
| Male | 8 | 13 | 21 |
| Ethnicity (NIH/OMB)(Participants) | MTP-131 (Bendavia™) | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 18 | 19 | 37 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | MTP-131 (Bendavia™) | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 18 | 20 | 38 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | MTP-131 (Bendavia™) | Placebo | Total |
|---|---|---|---|
| United States | 19 | 20 | 39 |
| Body Mass index(kg/m²) | MTP-131 (Bendavia™) | Placebo | Total |
|---|---|---|---|
| Mean | 26.5 ± 4.27 | 26.1 ± 2.82 | 26.3 ± 3.56 |
Ran from Jan 2015 to primary completion in Jul 2016, 17 months.
Results were first posted in Jun 2020, 3 years 11 months after primary completion.
Of 16 phase 2 interventional studies under Mitochondrial Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 85. This study's 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elamipretide
Stealth BioTherapeutics Inc. →